創作人：Chi-Huey Wong, Alice Yu, Ya-Jen Chang
智財權：US 7928077B2、 ZA 2011/01128、CA 2756053、 TW pending、 PCT pending
Alpha-Galactosylceramide is a glycolipid that was reported to have the capability to boost the human immune system in fighting cancers back in 1995. The research went pass various pre-clinical studies and raised hope. However, it failed to go beyond phase I trial. It turned out that while boosting the immunity fighting cancers, it also induces substances that suppress the immune functions, resulting in weak overall anti-cancer effects.
By using computer modeling technique, we have successfully designed and synthesized a series of compounds to have better binding to CD1 molecule than α-GalCer. Qualifying test against these compounds with human Natural Killer T cells showed glycolipids with an aromatic ring like attached to the tail end displayed higher IFN-g/IL-4 ratio than α-GalCer.
In vivo experiment on mice with aggressive lung cancer tumors and breast cancer tumors was performed. In breast cancer-bearing mice, treatment with the new glycolipids (C11, C13, C14, C16) inhibited the tumor growth rate by 75% of untreated group, as compared to 50% inhibition in mice treated with α-GalCer (C1). Meanwhile, the lung cancer-bearing mice treated with the new glycolipid had significantly prolonged survival time compared to those treated with α-GalCer. The treated mice appeared much healthier than the untreated group.
The invention indicates that novel α-GalCer analogs can be designed to favor Th1 biased immunity with greater anticancer efficacy than α-GalCer.
- Treatment of cancer
- Use as adjuvant for vaccine
- Treatment of autoimmune disorders
- Treatment of viral infection
- Glycolipids are expected to have minimal or no toxicities.
- Glycolipids have more potent adjuvant activities for vaccines than exiting adjuvants.
- There is a paucity of effective anti-viral agents. Glycolipids may ameliorate the severity of viral illness.
智財技轉處聯絡人：周宜黎 / 02-2787-2552 / email@example.com